Celldex Therapeutics (CLDX) Stock Price, Quote, News & History | Benzinga

SPY761.10−1.39%QQQ707.87−2.77%BTC/USD81,459.10−0.05%DIA518.00−0.59%GLD381.40−0.34%TLT80.06+0.11%

Celldex Therapeutics Inc (CLDX) Stock Price, Quote, News & History

CLDXNASDAQ

Trade with Public

Trade with Public

$27.53

-1.40-4.84%

Last update: Oct 16, 4:00 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$28.89

Close

$27.53

Volume / Avg.

975.51K / 1.33M

Day Range

$27.53 - $27.56

52 Wk Range

22.10 - 45.14

Market Cap

$2.18B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

23

Short Interest

16.64%

Days to Cover

3.81

Recent Celldex Therapeutics, Inc. News

Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.

Avi Kapoor

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.

Vandana Singh

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.

Avi Kapoor

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.

Vandana Singh

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-235.57M

Investing Cash Flow (TTM)

-67.13M

Financing Cash Flow (TTM)

327.11M

Free Cash Flow (TTM)

-242.11M

Capital Expenditure (TTM)

-6.54M

Net Change in Cash (TTM)

24.41M

Analyst Trends and Forecast

2

Jun

6

Jul

2

Aug

5

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.56B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

12697.16

PB Ratio (TTM)

3.18

Earnings Yield % (TTM)

-15.04%

Earnings Yield % (FWD)

-14.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.10

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$47.45M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-